Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30979886 | 0.99 | EGFR (0.42) | EGFRPDGFRBPDGFRAFGFR4KDM4E | |
| SCHEMBL30979887 | 0.97 | EGFR (0.43) | EGFRPDGFRBPDGFRAFGFR4KDM4E | |
| SCHEMBL241727 | 0.83 | EGFR (0.58) | EGFRPDGFRBPDGFRAFGFR4KDM4E | |
| Hydrochloric Acid SCHEMBL8814048 | 0.82 | EGFR (0.56) | EGFRPDGFRBPDGFRAFGFR4KDM4E | |
| Formaldehyde SCHEMBL28061098 | 0.79 | EGFR (0.53) | EGFRPDGFRBPDGFRAFGFR4KDM4E | |
| SCHEMBL30776773 | 0.78 | EHMT2 (0.63) | EHMT2EHMT1 | |
| SCHEMBL27987996 | 0.75 | PDGFRB (0.61) | EGFRPDGFRBPDGFRA | |
| SCHEMBL30001688 | 0.75 | ENPP1 (0.57) | EGFRPDGFRBPDGFRAFGFR4KDM4E | |
| SCHEMBL6000263 | 0.72 | EGFR (0.46) | EGFRFGFR4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30000483 | 0.72 | ENPP1 (0.59) | EGFRPDGFRBPDGFRAFGFR4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885PDGFRB 17/4885PDGFRA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.